Coya Therapeutics, Inc. (COYA)
2.80
-0.01
(-0.36%)
USD |
NASDAQ |
Nov 06, 10:20
Coya Therapeutics EPS Diluted (Quarterly) : -0.283 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.283 |
| March 31, 2026 | -0.3183 |
| December 31, 2025 | -0.2727 |
| September 30, 2025 | -0.1264 |
| June 30, 2025 | -0.3644 |
| March 31, 2025 | -0.437 |
| December 31, 2024 | -0.1745 |
| September 30, 2024 | -0.2642 |
| June 30, 2024 | -0.1939 |
| Date | Value |
|---|---|
| March 31, 2024 | -0.3494 |
| December 31, 2023 | 0.0879 |
| September 30, 2023 | -0.344 |
| June 30, 2023 | -0.3112 |
| March 31, 2023 | -0.2751 |
| December 31, 2022 | -0.3124 |
| September 30, 2022 | -0.4154 |
| December 31, 2021 | -0.1684 |
| September 30, 2021 | -0.1374 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Anixa Biosciences, Inc. | -0.0762 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.638M |
| Revenue (Quarterly) | 0.2437M |
| Total Expenses (Quarterly) | 6.882M |
| Enterprise Value | 22.74M |
| Gross Profit Margin (Quarterly) | 98.85% |
| Profit Margin (Quarterly) | -2.72K% |
| Earnings Yield | -35.73% |
| Normalized Earnings Yield | -32.83 |